Design and analytical validation of Nexthyro 2.0, a custom next-generation sequencing panel integrating DNA mutation profiling and RNA fusion detection for routine thyroid pathology specimens.
Aug 2026· Virchows Archiv· 0 citations· 36 references
Medicine
TL;DR
Nexthyro 2.0 represents a reliable local solution for thyroid molecular testing across cytological and histological specimens encountered in routine clinical practice and is validated as a locally deployable alternative to centralized tests.
Abstract
The increasing role of molecular testing in thyroid pathology, from the pre-operative stratification of indeterminate fine-needle aspiration (FNA) categories to the management of advanced carcinomas, has prompted the development of institution-specific custom NGS solutions as a locally deployable alternative to centralized tests. The aim of the present study is to validate a new custom NGS panel dedicated to the molecular analysis of routine thyroid pathology specimens. The panel was evaluated on thyroid cancer cell lines, 124 FFPE thyroid tissue specimens, and 43 FNA samples. Nexthyro 2.0 achieved a high sequencing success rate on both histological (100%) and cytological (95.3%) material, with analytical sensitivity down to 0.5% dilution point. Mutational profiles across thyroid neoplasm histotypes and FNA categories were consistent with established molecular-morphological correlates. Nexthyro 2.0 represents a reliable local solution for thyroid molecular testing across cytological and histological specimens encountered in routine clinical practice.
The clinical management of canine cutaneous mast cell tumour (cMCT) presents challenges. Treatment decisions are often informed by histopathological and molecular analysis of excisional biopsy samples, however, these may not always be available. Furthermore, current gold standard assays for the most informative...
Liam S. Hill, Jacob O. Evans, G. Tornillo et al.· BMC Veterinary Research· 0 citations
DNA methylation–based classification has become an essential adjunct to histopathology in central nervous system (CNS) tumor diagnostics. Although both fresh-frozen and formalin-fixed paraffin-embedded (FFPE) tissues are used for methylation profiling, comparative real-world data on their diagnostic performance r...
Jyotsna Singh, S. Mansoori, A. Suri et al.· Neuro-Oncology· 0 citations
Laboratory workflow optimization, particularly the adoption of hybrid-capture methodology, significantly improved NGS success rates in a nationwide nsNSCLC testing program, highlighting the need for targeted education and infrastructural investment to broaden equitable access to precision oncology in Brazil.
B. Araújo, R. Paes, A. Rodrigues et al.· Cancer Treatment and Researc...· 0 citations
Despite lower tumor cellularity and DNA concentration, appropriately selected biopsy specimens yielded high rates of evaluable sequencing and Tier I–II variant detection in this cohort, with no statistically significant differences in sequencing quality metrics or Tier I–II variant yield between specimen types.
Erdem Çomut, Ömer Atmış· OSMANGAZİ JOURNAL OF MEDICIN...· 0 citations
The scope of pre-analytical and early analytical methods used in clinical molecular laboratories can have vast effects on the quality and turnaround time for solid tumor next-generation sequencing assays. To learn more about various approaches, a survey of 24 academic laboratories within the Genomics Organization for A...
M. David, Jennifer J. D. Morrissette, N. Brown et al.· Academic Pathology· 0 citations
The transition from single-gene testing to comprehensive genomic profiling (CGP) is essential for precision oncology. The next generation sequence platform, enables the simultaneous detection of diverse variants and complex immuno-oncology biomarkers, providing a holistic view of the tumor genomic landscape....
Chung-Gue Huang, Shu-Li Yang, Chang-Fu Kuo et al.· Clinical Chemistry· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.